JAYPIRCA® (pirtobrutinib)
for BTK-Resistant Chronic Lymphocytic Leukemia
Patient Background
An 68-year-old homemaker from Mysuru, Karnataka, had been living with Chronic Lymphocytic Leukemia (CLL) for nearly a decade. She developed resistance to covalent BTK inhibitors, with progressive lymphadenopathy and worsening fatigue.
Her treating oncologist recommended JAYPIRCA (pirtobrutinib)—a next-generation non-covalent BTK inhibitor with efficacy in resistant CLL.
Regulatory Barriers
Jaypirca was unavailable in India, and previous treatment delays had already impacted quality of life. MitoGENE was contacted to explore NPP access.
MitoGENE’s Structured Approach
- Confirmed eligibility under CDSCO NPP
- Coordinated prescription justification and molecular resistance documentation
- Ensured compliant import under Form 12B
Treatment & Outcomes
JAYPIRCA (pirtobrutinib) was successfully imported and administered as per the treatment plan. The patient tolerated therapy well and continued treatment under close medical supervision.